Scienture Expands REZENOPY™ Reach to 2,000 U.S. Addiction Treatment…

Event summary

Scienture has signed an exclusive distribution agreement to expand REZENOPY™ access to ~2,000 U.S. opioid treatment clinics and addiction centers.
The deal complements Scienture’s existing commercialization strategy, which includes wholesalers, GPOs, and other distributors.
REZENOPY™ is the highest-dose FDA-approved naloxone nasal spray, targeting opioid overdose emergencies.
The U.S. naloxone market generated $140M in annual sales across 9.8M units as of July 2026 (IQVIA data).
Scienture acquired U.S. commercialization rights for REZENOPY™ in March 2025, following FDA approval in April 2024.

The big picture

Scienture’s deal underscores the strategic importance of specialized distribution channels in the opioid treatment space. With the U.S. naloxone market valued at $140M, this partnership enhances REZENOPY™’s accessibility while complementing Scienture’s broader commercialization strategy. The move aligns with industry trends favoring targeted, high-dose naloxone solutions amid rising opioid overdose risks.

What we're watching

Market Penetration: How quickly REZENOPY™ adoption scales within the addiction treatment center network.
Revenue Contribution: Whether this channel becomes a meaningful revenue driver alongside other distribution efforts.
Competitive Positioning: The pace at which Scienture can differentiate REZENOPY™ in a $140M naloxone market.